These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
936 related articles for article (PubMed ID: 29903896)
1. Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas. Dankner M; Lajoie M; Moldoveanu D; Nguyen TT; Savage P; Rajkumar S; Huang X; Lvova M; Protopopov A; Vuzman D; Hogg D; Park M; Guiot MC; Petrecca K; Mihalcioiu C; Watson IR; Siegel PM; Rose AAN Clin Cancer Res; 2018 Dec; 24(24):6483-6494. PubMed ID: 29903896 [TBL] [Abstract][Full Text] [Related]
2. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. Shattuck-Brandt RL; Chen SC; Murray E; Johnson CA; Crandall H; O'Neal JF; Al-Rohil RN; Nebhan CA; Bharti V; Dahlman KB; Ayers GD; Yan C; Kelley MC; Kauffmann RM; Hooks M; Grau A; Johnson DB; Vilgelm AE; Richmond A Clin Cancer Res; 2020 Jul; 26(14):3803-3818. PubMed ID: 32234759 [TBL] [Abstract][Full Text] [Related]
14. A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with Sullivan RJ; Weber J; Patel S; Dummer R; Carlino MS; Tan DSW; Lebbé C; Siena S; Elez E; Wollenberg L; Pickard MD; Sandor V; Ascierto PA Clin Cancer Res; 2020 Oct; 26(19):5102-5112. PubMed ID: 32669376 [TBL] [Abstract][Full Text] [Related]
15. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma. Rose AAN Drugs Today (Barc); 2019 Apr; 55(4):247-264. PubMed ID: 31050693 [TBL] [Abstract][Full Text] [Related]
16. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Menzies AM; Long GV Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796 [TBL] [Abstract][Full Text] [Related]
17. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767 [TBL] [Abstract][Full Text] [Related]
18. BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress. Roulstone V; Pedersen M; Kyula J; Mansfield D; Khan AA; McEntee G; Wilkinson M; Karapanagiotou E; Coffey M; Marais R; Jebar A; Errington-Mais F; Melcher A; Vile R; Pandha H; McLaughlin M; Harrington KJ Mol Ther; 2015 May; 23(5):931-942. PubMed ID: 25619724 [TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489 [TBL] [Abstract][Full Text] [Related]
20. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases. Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]